Inducing tolerance by intranasal administration of long peptides in naive and primed CBA/J mice

Journal of Immunology

Volumn 165, Issue 6, 2000, Pages 3497-3505

  Astori, M ^a   Von Garnier, C ^a   Kettner, A ^a   Dufour, N ^a   Corradin, G ^a   Spertini, F ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; PEPTIDE DERIVATIVE; PHOSPHOLIPASE A; VACCINE;

ALLERGY; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

EID: 0034665515     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.6.3497     Document Type: Article

References (55)

1. Honeybee venom allergy: Results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients
2. Discontinuing venom immunotherapy: Outcome after five years
3. Long-term protection after stopping venom immunotherapy: Results of re-stings in 200 patients
4. + T cells from allergic individuals
5. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures
6. 2-derived peptides by conventional bee venom immunotherapy
7. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: Two key steps in specific immunotherapy
8. 2 induces specific T cell anergy in patients allergic to bee venom
9. Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils
10. Adverse reactions associated with skin testing and immunotherapy
11. Induction of tolerance via the respiratory mucosa
12. Clinical efficacy of sublingual-swallow immunotherapy: A double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis
13. Randomized controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis
14. Treatment of cat allergy with T-cell reactive peptides
15. Fel d 1 peptides: Effect on skin tests and cytokine synthesis in cat-allergic human subjects
16. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats
17. T-cell responses to allergens: Epitope-specificity and clinical relevance
18. Delineation of PLA(2) epitopes using short or long overlapping synthetic peptides: Interest for specific immunotherapy
19. A simple and rapid procedure for the purification of synthetic polypeptides by a combination of affinity chromatography and methionine chemistry
20. Incorporation of cells into an ELISA system enhances antigen-driven lymphokine detection
21. Isotype-associated recognition of allergen epitopes and its modulation by antigen dose
22. Specific T-cell tolerance may be preceded by a primary response
23. Oral tolerance mechanisms and therapy of autoimmune disease
24. Peripheral immune tolerance blocks clonal expansion but fails to prevent the differentiation of Thl cells
25. Anergy and cytokine-mediated suppression as distinct superantigen- induced tolerance mechanisms in vivo
26. Immunoregulatory role of IL-10 during superantigen-induced hyporesponsiveness in vivo
27. Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo
28. Modifications of CD8((+)) T cell function during in vivo memory or tolerance induction
29. + T cells
30. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
31. + T cells
32. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor β after antigen-specific triggering
33. Mechanisms of oral tolerance
34. Peripheral deletion of antigen-reactive T cells in oral tolerance
35. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy
36. Oral tolerance: Immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens
37. Peripheral tolerance of Th2 lymphocytes induced by continuous feeding of ovalbumin
38. + T cells or interferon (IFN)-γ in a marine model of allergen sensitization
39. Regulation of antigen-specific IgE, IgG1, and mast cell responses to ingested allergen by mucosal tolerance induction
40. + T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type
41. 2
42. 2
43. Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation
44. + T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production
45. + T cells
46. How some T cells escape tolerance induction
47. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy
48. T-cell deletion in high antigen dose therapy of autoimmune encephalomyelitis
49. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice
50. Characterization of the specificity and duration of T cell tolerance to intranasally administered peptides in mice: A role for intramolecular epitope suppression
51. 2
52. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: Potential use of hypoallergenic isoforms for immunotherapy
53. Modulation of IgE reactivity of allergens by site-directed mutagenesis: Potential use of hypoallergenic variants for immunotherapy
54. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation
55. + T helper cells engineered to produce latent TGF-β1 reverse allergen-induced airway hyperreactivity and inflammation